New data on rezpegaldesleukin supporting long-term durability and disease improvement in patients with alopecia areata and atopic dermatitis will be presented at the EADV Congress 2026, according to an announcement carried by Morningstar.

The upcoming congress presentation adds to the clinical record of rezpegaldesleukin, an investigational IL-2 pathway–targeting biologic being developed for autoimmune and inflammatory skin disease. The two indications at the center of the new data — alopecia areata and atopic dermatitis — represent patient populations where durable response remains an unmet need.

What is rezpegaldesleukin?

Rezpegaldesleukin is a first-in-class investigational agent designed to modulate T-cell activity through the IL-2 pathway. Developers have positioned it as a potential treatment for T-cell–driven diseases, and dermatology has emerged as a key therapeutic frontier, spanning both alopecia areata and atopic dermatitis.

No approved therapy profiled in the announcement matches rezpegaldesleukin's mechanism, which places the compound among the mechanistically distinct candidates clinicians are tracking in immune-mediated dermatology.

Why long-term durability matters here

For alopecia areata, sustained regrowth is the hurdle that has limited enthusiasm around earlier therapies, with relapse common after treatment stops. In atopic dermatitis, long-term control — maintaining clear or near-clear skin over years rather than weeks — defines the difference between a maintenance drug and a flare-responsive one.

The announcement frames the new dataset specifically around durability and disease improvement, signaling that the EADV 2026 presentations will speak to the questions payers and prescribers ask first: how long responses hold, and in how many patients.

What the EADV 2026 presentation covers

According to the Morningstar item, the data to be presented support:

• Long-term durability of response in alopecia areata
• Long-term durability of response in atopic dermatitis
• Disease improvement across the studied populations

The announcement does not specify the trial design, cohort sizes, or the exact duration of follow-up behind the durability claims; those details are expected to accompany the full congress presentations.

The road ahead

EADV 2026 will give dermatologists the first structured look at the long-term dataset, and the durability findings — once full efficacy and safety numbers are on the table — will shape where rezpegaldesleukin sits in the future treatment sequence for both diseases.